Exhibit 99.1

Form 51-102F3

MATERIAL CHANGE REPORT

Item 1.	Name and Address of Reporting Issuer
	Cardiome Pharma Corp. (“Cardiome” or the “Corporation”) 1441 Creekside Drive, 6th floor Vancouver, BC V6J 4S7

Item 2.	Date of Material Change
	June 29, 2015

Item 3.	News Release
	June 29, 2015 – Vancouver, Canada.

Item 4.	Summary of Material Change
	Cardiome and SteadyMed enter into a license agreement for the commercialization rights to Trevyent ® outside the United States.

Item 5.	5.1 - Full Description of Material Change
	See press release on exhibit 99.2.
	5.2 – Disclosure for Restructuring Transactions
	Not applicable.

Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102
	Not applicable.

Item 7.	Omitted Information
	Not applicable.

Item 8.	Executive Officer
	Jennifer Archibald, Chief Financial Officer Telephone: 604-677-6905.

Item 9.	Date of Report
	This Material Change Report is dated June 29, 2015.